As per FMI Analysts, the global preventive medicine market is estimated to be valued at US$ 396.63 billion in the current year 2023. According to the analysis report by FMI, the overall market is projected to expand at a CAGR of 8.4% during the forecast period from 2023 to 2033. By following this robust growth rate, the global market share value is expected to reach nearly US$ 886.59 billion by 2033.
Pharmacies have identified a sustainable model for sales of preventive medicine, by improving awareness of people along with expanding availability. Access to education has contributed to the growth in demand for preventive medicine as well.
The journal Health Affairs reports that the United States of America is going to save only 0.2% of its healthcare expenditures even when 90% of the population demands preventive medicines. Further, reforming attitudes of individuals along with increasing the supply across local stores has also contributed to this growth in sales of preventive medicine in the last couple of years.
Europe’s preventive market share is growing well with a market share of 36% as a result of the success of risk factor epidemiology in the region. It led to the enactment of a wide range of preventive measures, such as legislation to limit tobacco advertising and smoking in public places, and community-based health education programs, propelling the demand for preventive medicine indirectly
Asia may record significant growth in sales of preventive medicine due to its huge population that still believes in preventive measures, but lack of awareness may also negatively affect the market. China and India might also benefit from the rise in private organizations managing public hospitals and health insurance companies for sustaining the market share in the region.
| Report Attributes or Data Points | Details |
|---|---|
| Global Preventive Medicine Market Valuation in 2022 | US$ 371.88 billion |
| Estimated Global Market Share in 2023 | US$ 396.63 billion |
| Forecasted Global Market Size by 2033 | US$ 886.59 billion |
| Projected Global Market Growth Rate from 2023 to 2033 | 8.4% CAGR |
| Historical Market Growth Rate from 2018 to 2022 | 5.5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The worldwide sales and consumption of preventive medicines, in terms of value, was mere US$ 284.6 billion in the year 2018. The global market expanded at an average of 5.5% over the years between 2018 and 2022 because of rising prices for medicines, medical devices, medical treatments, and surgical procedures.
Pharmaceutical companies are generating huge demand for preventive medicine as they struggle with their current model, which is neither profitable nor fulfilling. Furthermore, other studies have similarly demonstrated that preventive measures do not increase life expectancy which has posed a negative impact on the demand for preventive medicines.
The preventative medicine market has also not yet fully realized its potential to limit healthcare expenditures because the return on investment has never been explained. It has also kept people from becoming involved in this field, affecting the demand for preventive medicine to certain degrees.
| Category | By Specialty Area |
|---|---|
| Top Segment | Public Health and General Preventive Medicine |
| Market Share in Percentage | 43.2% |
| Category | By Distribution Channel |
|---|---|
| Top Segment | Hospitals |
| Market Share in Percentage | 37.8% |
There are several factors contributing to the rise in demand for preventive medicine in the global market, including the rising prices of medicines, medical devices, treatments, and surgical procedures. Also, it seems that pharmaceutical companies are taking an interest in sales of preventive medicine as they are facing problems with their traditional pharmaceutical business model, which is neither profitable nor sufficiently fulfilling the market needs, affecting the business worldwide.
The demand for preventive medicine has received a lot of traction in the healthcare sector recently. Therefore, the pharmaceutical industry has identified and promoted a sustainable model of collaborating with regional players, which has contributed greatly to the growth of the overall market share. This has also posed a setback for the sales of preventive medicine in the market, mainly because a broad coalition of pharmacy companies includes big players and small start-ups, as well as corporate and academic organizations.
Another obstacle to increasing the demand for preventive medicine is its potential to limit healthcare expenditures because the return on investment was never clearly communicated by private players.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| North America | 43.2% |
| Europe | 36.7% |
Principal Consultant
With a market share of 42%, North America lags behind other countries when it comes to sales of preventive medicine in terms of volume because players are not as interested as in Asia Pacific countries.
A vast coalition of drug companies and start-ups with commercial organizations and academic institutions is needed, which is rare in the country for North America’s market share to succeed. This is one of the key hurdles for the sales of preventive medicine by the market players in the United States of America and Canada.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| The United States | 38.3% |
| Germany | 8.5% |
| Japan | 3.3% |
Europe’s market share is growing well with a 36% market share value, thanks to the success of risk factor epidemiology in the region, which has led to a wide range of preventive measures. Also, several countries in Europe have been conducting campaigns to reduce cardiovascular disease burden, and Asia may support its significantly growing demand for preventive medicine. However, a lack of awareness could also impact the sales of preventive medicine
| Regional Markets | CAGR (2023 to 2033) |
|---|---|
| The United Kingdom | 5.9% |
| China | 10.3% |
| India | 8.4% |
| Australia | 7.5% |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Some of the leading companies operating in the global market include Novo Nordisk, Eli Lilly, Quanterix, Aetna Inc., Preventive Medical Health Care Co., LTD., Cancer Prevention Pharmaceuticals, Inc., Phoenix Medicine, American College of Preventive Medicine and USA, Preventive Medicine.
In preventive medicine, the example that stands out is immunizations, which are the best way to reduce the financial burden on the economy of any country from several life-threatening diseases. Also, cancer screenings for ovarian cancer, testicular cancer, and prostate cancer through PSA tests, and routine use of aspirin by cardiovascular patients are some of the key opportunities for market players to increase their sales of preventive medicine.
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 8.4% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization & Pricing | Available Upon Request |
The global sales of preventive medicine are anticipated to expand at 8.4% during the forecast period.
The global market is predicted to be valued at US$ 886.59 billion by 2033.
The global sales of preventive medicine were valued at US$ 371.88 billion in 2022.
The United States accounts for nearly 38.3% revenue share of the global market.
China is to witness a CAGR of 10.3% in sales of preventive medicine through 2033.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Specialty Areas
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Specialty Areas, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Specialty Areas, 2023 to 2033
5.3.1. Aerospace Medicine
5.3.2. Occupational Medicine
5.3.3. Public Health and General Preventive Medicine
5.4. Y-o-Y Growth Trend Analysis By Specialty Areas, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Specialty Areas, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channels
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channels, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channels, 2023 to 2033
6.3.1. Hospitals
6.3.2. Diagnostic Centers
6.3.3. Employers
6.4. Y-o-Y Growth Trend Analysis By Distribution Channels, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Distribution Channels, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.2. By Specialty Areas
8.2.3. By Distribution Channels
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Specialty Areas
8.3.3. By Distribution Channels
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Specialty Areas
9.2.3. By Distribution Channels
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Specialty Areas
9.3.3. By Distribution Channels
9.4. Key Takeaways
10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. U.K.
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Specialty Areas
10.2.3. By Distribution Channels
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Specialty Areas
10.3.3. By Distribution Channels
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Specialty Areas
11.2.3. By Distribution Channels
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Specialty Areas
11.3.3. By Distribution Channels
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Specialty Areas
12.2.3. By Distribution Channels
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Specialty Areas
12.3.3. By Distribution Channels
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Specialty Areas
13.2.3. By Distribution Channels
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Specialty Areas
13.3.3. By Distribution Channels
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Specialty Areas
14.2.3. By Distribution Channels
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Specialty Areas
14.3.3. By Distribution Channels
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. U.S.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Specialty Areas
15.1.2.2. By Distribution Channels
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Specialty Areas
15.2.2.2. By Distribution Channels
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Specialty Areas
15.3.2.2. By Distribution Channels
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Specialty Areas
15.4.2.2. By Distribution Channels
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Specialty Areas
15.5.2.2. By Distribution Channels
15.6. U.K.
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Specialty Areas
15.6.2.2. By Distribution Channels
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Specialty Areas
15.7.2.2. By Distribution Channels
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Specialty Areas
15.8.2.2. By Distribution Channels
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Specialty Areas
15.9.2.2. By Distribution Channels
15.10. Poland
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Specialty Areas
15.10.2.2. By Distribution Channels
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Specialty Areas
15.11.2.2. By Distribution Channels
15.12. Czech Republic
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Specialty Areas
15.12.2.2. By Distribution Channels
15.13. Romania
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Specialty Areas
15.13.2.2. By Distribution Channels
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Specialty Areas
15.14.2.2. By Distribution Channels
15.15. Bangladesh
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Specialty Areas
15.15.2.2. By Distribution Channels
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Specialty Areas
15.16.2.2. By Distribution Channels
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Specialty Areas
15.17.2.2. By Distribution Channels
15.18. China
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Specialty Areas
15.18.2.2. By Distribution Channels
15.19. Japan
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Specialty Areas
15.19.2.2. By Distribution Channels
15.20. South Korea
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Specialty Areas
15.20.2.2. By Distribution Channels
15.21. GCC Countries
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Specialty Areas
15.21.2.2. By Distribution Channels
15.22. South Africa
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Specialty Areas
15.22.2.2. By Distribution Channels
15.23. Israel
15.23.1. Pricing Analysis
15.23.2. Market Share Analysis, 2022
15.23.2.1. By Specialty Areas
15.23.2.2. By Distribution Channels
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Specialty Areas
16.3.3. By Distribution Channels
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Novo Nordisk
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Eli Lilly
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Quanterix
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Aetna Inc.
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Preventive Medical Health Care Co.
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. LTD.
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Cancer Prevention Pharmaceuticals, Inc.
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Phoenix Medicine
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. American College of Preventive Medicine
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. USA, Preventive Medicine.
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Preventive Medicine Market
